The effect of intravenous pamidronate treatment for type i osteogenesis imperfecta patients have on their bone mineral density, fracture rate, and mobility

ÖZTEMÜR Z. , ÖZTÜRK H. , Circi E., BULUT O. , ÜNER S., ALTUN A. , ...More

HEALTHMED, vol.6, no.10, pp.3425-3429, 2012 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 6 Issue: 10
  • Publication Date: 2012
  • Title of Journal : HEALTHMED
  • Page Numbers: pp.3425-3429


Objective: Osteogenesis imperfecta (OI) is a genetic disorder caused by the mutation in encoding collagen type I, and characterised by fragile bone and reduced bone mineral density. The purpose of this study was to analyse the effects siklik intravenous pamidronate treatment has on the bone mineral density and the fracture rateand mobility.